Skip to content

Media Hub

An Interview with Holger Wesche

Holger Wesche
Chief Scientific Officer
Harpoon Therapeutics

What do you feel is the biggest challenge preventing wide scale use of cell engagers in patients?

I think the biggest challenge in the field of T cell engagers is our limited understanding of how to manage cytokines in the clinic. Cytokines are an integral part of any immune response, and required for robust efficacy. However, cytokines can also be a significant safety liability.

Unfortunately we do not yet have the understanding or tools to manage cytokines efficiently in the clinic...